MedPath

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Registration Number
NCT00072462
Lead Sponsor
Queen Mary University of London
Brief Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen. It is not yet known whether tamoxifen is more effective than anastrozole in preventing breast cancer after surgery for ductal carcinoma in situ.

PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works compared to anastrozole in treating postmenopausal women who have undergone surgery to remove ductal carcinoma in situ.

Detailed Description

OBJECTIVES:

Primary

* Compare the efficacy of adjuvant tamoxifen vs anastrozole, in terms of local control and prevention of contralateral disease, in postmenopausal women with locally excised ductal carcinoma in situ.

* Compare side effect profiles of these drugs in these patients.

Secondary

* Compare the efficacy of these drugs, according to the receptor status of the primary or recurrent cancer in these patients.

* Compare the rate of breast cancer recurrence and growth of new contralateral tumors after cessation of treatment with these drugs in these patients.

* Compare breast cancer mortality in patients treated with these drugs.

* Compare the effect of these drugs on other cancers, cardiovascular disease, fracture rates, and non-breast cancer deaths in these patients.

* Compare the tolerability and acceptability of side effects experienced by patients treated with these drugs.

OUTLINE: This is a randomized, double-blind, multicentre study. Patients are stratified according to participating centre. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral tamoxifen and oral placebo once daily.

* Arm II: Patients receive oral anastrozole and oral placebo once daily. In both arms, treatment continues for 5 years in the absence of disease recurrence or unacceptable toxicity.

Patients are followed annually for 5 years and a further 5 years (minimum) off treatment.

Peer Reviewed and Funded by Cancer Research UK. Sponsored by Queen Mary University of London

ACTUAL ACCRUAL: A total of 2,980 patients were accrued for this study over 9 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
2980
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Tamoxifentamoxifen citrate-
AnastrozoleAnastrozole-
Primary Outcome Measures
NameTimeMethod
Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral TumoursDate of the breast cancer occurrence is defined as the date of the confirmation of the specific event (from randomisation to date of occurrence). Data presented is from randomisation to study completion, median follow-up was 11.6 years (IQR: 9.9-13.5).
Secondary Outcome Measures
NameTimeMethod
Number of Participants With ER+ Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral TumoursDate of the breast cancer occurrence is defined as the date of the confirmation of the specific event (from randomisation to date of occurrence). Data presented is from randomisation to study completion, median follow-up was 11.6 years (IQR: 9.9-13.5).
Number of Participants With ER- Breast Cancer RecurrenceDate of the breast cancer occurrence is defined as the date of the confirmation of the specific event (from randomisation to date of occurrence). Data presented is from randomisation to study completion, median follow-up was 11.6 years (IQR: 9.9-13.5).
Number of Breast Cancer DeathsDate of the death is defined as the date of the confirmation of the specific event (from randomisation to date of occurrence). Data presented is from randomisation to study completion, median follow-up was 11.6 years (IQR: 9.9-13.5).
Number of Non-breast Cancer DeathsDate of the death is defined as the date of the confirmation of the specific event (from randomisation to date of occurrence). Data presented is from randomisation to study completion, median follow-up was 11.6 years (IQR: 9.9-13.5).

Trial Locations

Locations (97)

Mid-Western Regional Hospital

🇮🇪

Limerick, Ireland

Nottingham City Hospital

🇬🇧

Nottingham, England, United Kingdom

Centre for Cancer Research and Cell Biology at Queen's University Belfast

🇬🇧

Belfast, Northern Ireland, United Kingdom

Royal Marsden Hospital

🇬🇧

London, Please Select, United Kingdom

Countess of Chester Hospital

🇬🇧

Chester, United Kingdom

Queens Hospital Burton

🇬🇧

Burton, United Kingdom

Belgium

🇧🇪

Leuven, Belgium

Chile

🇨🇱

Santiago, Chile

Hungary

🇭🇺

Szeged, Hungary

Inselspital Bern

🇨🇭

Bern, Switzerland

Kantonspital

🇨🇭

Luzern, Switzerland

York Hospital

🇬🇧

York, United Kingdom

Royal Infirmary of Edinburgh at Little France

🇬🇧

Edinburgh, Scotland, United Kingdom

University College Hospital

🇮🇪

Galway, Ireland

Oncocare Sonnenhof-Klinik Engeriedspital

🇨🇭

Bern, Switzerland

Colchester General Hospital

🇬🇧

Colchester, England, United Kingdom

Austrian Breast & Colorectal Cancer Study Group

🇦🇹

Vienna, Austria

St. Vincent's University Hospital

🇮🇪

Dublin, Ireland

Sir Paul Boffa Hospital,

🇲🇹

Floriana, Malta

Hopital Cantonal Universitaire de Geneve

🇨🇭

Geneva, Switzerland

Newcastle Upon Tyne Hospitals NHS Trust

🇬🇧

Newcastle-Upon-Tyne, England, United Kingdom

St. Thomas' Hospital

🇬🇧

London, England, United Kingdom

Ninewells Hospital

🇬🇧

Dundee, Scotland, United Kingdom

Cork Infirmary

🇮🇪

Cork, Ireland

Cork University Hospital

🇮🇪

Cork, Ireland

Beaumont Hospital

🇮🇪

Dublin, Ireland

Sligo General Hospital

🇮🇪

Sligo, Ireland

The Adelaide and Meath Hospital

🇮🇪

Tallaght, Ireland

Centre Hospitalier Universitaire Vaudois

🇨🇭

Lausanne, Switzerland

Regionalspital

🇨🇭

Thun, Switzerland

Frenchay Hospital

🇬🇧

Bristol, England, United Kingdom

Royal South Hants Hospital

🇬🇧

Southampton, England, United Kingdom

Leeds Cancer Centre at St. James's University Hospital

🇬🇧

Leeds, England, United Kingdom

Cheltenham General Hospital

🇬🇧

Cheltenham, United Kingdom

European Institute of Oncology

🇮🇹

Milan, Italy

Australia

🇦🇺

Newcastle, Australia

Institut Sainte Catherine

🇫🇷

Avignon, France

Derbyshire Royal Infirmary

🇬🇧

Derby, United Kingdom

Institut Bergonie

🇫🇷

Bordeaux, France

Polyclinique Bordeaux Nord Aquitaine

🇫🇷

Bordeaux, France

CHU Hopital A. Morvan

🇫🇷

Brest, France

Clinique Tivoli

🇫🇷

Bordeaux, France

Centre Jean Perrin

🇫🇷

Clermont-Ferrand, France

Centre Regional Francois Baclesse

🇫🇷

Caen, France

CMC Les Ormeaux

🇫🇷

Le Havre, France

Lincoln County Hospital

🇬🇧

Lincoln, United Kingdom

Centre Hospitalier de Lagny

🇫🇷

Lagny Sur Marne, France

Centre de Lutte Contre le Cancer Georges-Francois Leclerc

🇫🇷

Dijon, France

Centre Hospital Regional Universitaire de Limoges

🇫🇷

Limoges, France

Centre Oscar Lambret

🇫🇷

Lille, France

Clinique Saint - Pierre

🇫🇷

Perpignan, France

Centre Regional Rene Gauducheau

🇫🇷

Nantes, France

Centre Hospitalier de Mulhouse

🇫🇷

Mulhouse, France

Institut Jean Godinot

🇫🇷

Reims, France

Centre Eugene Marquis

🇫🇷

Rennes, France

Centre Henri Becquerel

🇫🇷

Rouen, France

Institut Gustave Roussy

🇫🇷

Villejuif, France

Institut Claudius Regaud

🇫🇷

Toulouse, France

Germany

🇩🇪

Neu-Isenburg, Germany

Switzerland(St. Gallen)

🇨🇭

(St. Gallen), Switzerland

Sweden

🇸🇪

Lund, Sweden

Ospedale Beata Vergine

🇨🇭

Mendrisio, Switzerland

Tumor Zentrum ZeTup St. Gallen und Chur

🇨🇭

St. Gallen, Switzerland

Turkey(Istanbul University)

🇹🇷

Istanbul, Turkey

Whittington Hospital

🇬🇧

London, England, United Kingdom

Christie Hospital

🇬🇧

Manchester, England, United Kingdom

St. Bartholomew's Hospital

🇬🇧

London, Please Select, United Kingdom

University Hospital of Wales

🇬🇧

Cardiff, Wales, United Kingdom

Royal Bournemouth Hospital

🇬🇧

Bournemouth, United Kingdom

Royal Bolton Hospital

🇬🇧

Bolton, United Kingdom

Royal Sussex County Hospital

🇬🇧

Brighton, United Kingdom

Aberdeen Royal Infirmary

🇬🇧

Aberdeen, United Kingdom

Tameside General Hospital

🇬🇧

Ashton under Lyne, United Kingdom

St Lukes Hospital

🇬🇧

Bradford, United Kingdom

Bristol Infirmary

🇬🇧

Bristol, United Kingdom

St Margaret's Hospital

🇬🇧

Epping, United Kingdom

Grantham & District Hospital

🇬🇧

Grantham, United Kingdom

Conquest Hospital, The Ridge

🇬🇧

Hastings, United Kingdom

Royal Devon and Exeter Hospital

🇬🇧

Exeter, United Kingdom

Frimley Park Hospital NHS Trust

🇬🇧

Frimley, United Kingdom

Airedale General Hospital

🇬🇧

Keighley, United Kingdom

Huddersfield Royal Infirmary

🇬🇧

Huddersfield, United Kingdom

Leeds St James.

🇬🇧

Leeds, United Kingdom

Royal Hospital Haslar

🇬🇧

Portsmouth, United Kingdom

Derriford Hospital

🇬🇧

Plymouth, United Kingdom

Scarborough NHS Trust

🇬🇧

Scarborough, United Kingdom

Weston Park Hospital

🇬🇧

Sheffield, United Kingdom

Staffordshire General Hospital

🇬🇧

Stafford, United Kingdom

Clayton Hospital, Northgate

🇬🇧

Wakefield, United Kingdom

Welwyn Garden City Hospital

🇬🇧

Welwyn, United Kingdom

Wishaw General Hospital

🇬🇧

Wishaw, United Kingdom

Singleton Hospital

🇬🇧

Swansea, United Kingdom

Treliske Royal Cornwall Hospital

🇬🇧

Truro, United Kingdom

Worthing Hospital

🇬🇧

Worthing, United Kingdom

Yeovil District Hospital

🇬🇧

Yeovil, United Kingdom

Castle Hill Hospital

🇬🇧

Hull, United Kingdom

Royal Liverpool University Hospital

🇬🇧

Liverpool, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath